Member Info for hazrat

Hawkhead, given p=. 0132 why are you worried about placebo effect? Trying to understand your scepticism.

So there we go, people moaning about the lack of director buys and here they are.

Because you must be going for a bite with that question

Haha Parity

Couldn't agree more Yesman. It was well telegraphed that there was only funding for stage 1 of phase 3 but when it is mentioned again in an update, the SP drops. Simon Thomas decides to take profits so the SP drops, the same man who tipped Cenkos before it tanked and Patisserie Valerie before it went bust. No wonder he is nervous and looking to lock in gains. Amazing how few investors have a mind of their own.

So Rhodi what is your opinion on the placebo effect and p=0.0132 in phase 2 at 2% dose?

And that is at just 0. 2% dose

Hawkhead P= 0.0132 in the phase 2 trial. Why are you so concerned by the placebo effect?

Think the key difference is that CSD500 doesn't use dermasys technology and so is more of a gimmick than a serious play like med

End of trial announcement should be any day now. Last recruitment complete 19th June and 12 week cycle.

Reaction is typical in a company with so many PI. There was no new news yesterday - it was well telegraphed that there was only enough cash to get through the current study, same applies the results time line.

I reckon the drop is because a lot of PI have invested without doing any research and so have been spooked by mention of the above. Then you have a lot of people who have made a profit from the recent increases and so are cautiously crystallising that profit.

Talk of further dilution

3 levels of dose on trial and a placebo. Assuming an even split, 25% of the 500 were therefore, on placebo. There has been a lot of chat on this board about the risk of the placebo effect. Interesting to know if the 20% not progressing came from the placebo/0.2% group.

80% of the 500

What a great idea. Can't see how it is bad news.

Sorry, Badger not Bruce.

Not really Bruce because it is an issue of shares to subsidiary management. They have hit their earn out targets and so are getting paid as part of the acquisition deal. So very different from a run of the mill AIM con.

On track for a 4% dividend yield next year.

Strong indication all is well

Unlike funding circle this company makes money.

Said it before, rebrand as a fintech challenger and SP will go up 1000%